User Notice: The site will be occasionally unavailable due to scheduled maintenance this weekend. Please accept our apologies for any inconvenience.

Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Reneuron Group Plc LSE:RENE London Ordinary Share GB00BF5G6K95 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.00 -0.67% 147.50 145.00 150.00 149.50 147.50 149.50 68,911 16:09:39
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 6.1 -13.9 -35.9 - 84

Reneuron Share Discussion Threads

Showing 7951 to 7975 of 8300 messages
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
DateSubjectAuthorDiscuss
27/7/2020
16:57
Oh well, makes rene look to be a loser. 74 patients as against 10! Much larger trial. Exozome the only hope?
rayrac
27/7/2020
14:18
hxxps://www.businesswire.com/news/home/20200727005222/en/
crt131
21/7/2020
16:00
Funding round soon
sambocoole
14/7/2020
18:00
He's got quite some money.
small crow
14/7/2020
16:58
Whatever, that’s quite a holding.
rayrac
14/7/2020
15:27
Typo or 15 months 5. Date on which the threshold was crossed or reached: 5 March 2019 hxxps://www.marketscreener.com/business-leaders/Richard-Griffiths-05J8QH-E/biography/
xow98
14/7/2020
15:21
Anyone know how that investor gets away with not filing until over 3 months after change?
small crow
29/6/2020
12:37
Encouraging results. It will be interesting to see the results come in from the new sample of patients once things begin - lessons should have been learned from sample 1 and so, hopefully, even more convincing improvements.
small crow
29/6/2020
09:07
martin - 18 months is only 1 patient hence not really comparable with the others - he's obviously done exceptionally well on the treatment. Results remain very good for all patients (except those who suffered surgical problems obviously) but most striking to me is the improvement in the untreated eyes. Normally they would be expected to continue deteriorating to more or less full blindness, but here they're also improving quite markedly. Let's hope it continues.
supernumerary
29/6/2020
07:39
Pretty amazing jump from 12 to 18 months, if I have read it correctly on phone. Also very pleased that one of the blinded patients got back to baseline
martinfrench
29/6/2020
07:17
More good news today, should help support the sp
ayl30
28/6/2020
11:29
Lauders, Thanks for that. I think exosomes will turnout to be very useful and valuable, but I've been wrong before! Let's hope we are inside the tent.
small crow
28/6/2020
06:37
Been having a look at the exosome companies and deals out of my own personal interest: 1) Sarepta Inks Agreement With Codiak to Develop Gene Therapies (already mentioned here) - Https://finance.yahoo.com/news/sarepta-inks-agreement-codiak-develop-142702847.html 2) InnoCan and Ramot at Tel Aviv University are collaborating on a new, revolutionary exosome-based technology that targets both central nervous system (CNS) indications and the Covid-19 Corona Virus. CBD-Loaded Exosomes hold the potential to provide a highly synergistic effect of anti-inflammatory properties and help in the recovery of infected lung cells. Https://innocanpharma.com/ 3) British biotech Evox Therapeutics has signed a collaboration deal worth up to €1.1B with US big pharma Eli Lilly to develop RNA drugs that are delivered in exosomes to the brain to treat neurological diseases. Https://www.labiotech.eu/brain/evox-therapeutics-eli-lilly/ 4) Exopharm (ASX:EX1) reveals promising Plexaris anti-cancer results. + The company combined a typical lung cancer treatment drug called doxorubicin with its Plexaris exosome product to create a new treatment, dubbed Plexodox. Https://themarketherald.com.au/exopharm-asxex1-reveals-promising-plexaris-anti-cancer-results-2020-05-25/ 5) VivaZome Therapeutics and the University of Adelaide have entered into a series of agreements encompassing licensing of technology, access to stem cells and conduct of research, all in support of VivaZome’s mission to develop and commercialise exosome-based therapeutics. Https://www.miragenews.com/vivazome-licenses-university-of-adelaide-stem-cell-technology/ 6) MDimune Signed a Research Collaboration Agreement with Paracelsus Medical University for EV Therapeutics Development. + EVs, especially exosomes, have emerged as a novel therapeutic with their roles in intercellular communications. Https://www.biospace.com/article/mdimune-signed-a-research-collaboration-agreement-with-paracelsus-medical-university-for-ev-therapeutics-development/ 7) Avalon GloboCare Partners with HydroPeptide. + Avalon GloboCare Corp. (NASDAQ: AVCO) is a clinical-stage, vertically-integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy and exosome technology. Https://newyork.citybizlist.com/article/608528/avalon-globocare-partners-with-hydropeptide 8) Orgenesis has added muscle-derived stem cells to its offering through a manufacturing joint venture with Revatis. The partnership will supply developers of autologous cell therapies with exosomes and other cellular products obtained from muscle-derived mesenchymal stem cells (mdMSCs). Https://bioprocessintl.com/bioprocess-insider/deal-making/orgenesis-signs-muscle-derived-stem-cell-pact-with-revatis/ 9) Evox and Takeda sign deal to collaborate on rare disease treatments. + The targeted and non-targeted exosomes offer a highly differentiated platform with the potential to enhance tissue delivery for a variety of payloads like mRNA and proteins. Https://www.europeanpharmaceuticalreview.com/news/116115/evox-and-takeda-sign-deal-to-collaborate-on-rare-disease-treatments/ 10) Exosome specialist Exopharm (EX1) has reported some strong results for its Cevaris product in treating erectile dysfunction (ED). Https://themarketherald.com.au/exopharm-ex1-delivers-positive-results-for-potential-erectile-dysfunction-treatment-2020-02-20/ These are just the first ten I found and there seem to be many more out there. Looks like this could be a very exciting place to be as RENE inks new deals and hopefully develops exosomes further for the benefit of many patients. This is also worth a read: Https://finance.yahoo.com/news/newfound-cell-defense-system-features-160000044.html
lauders
25/6/2020
12:28
ReNeuron Group inks research evaluation deal with US firm - At 12.26 +3.50 (2.64%) 25 Jun, 11:48 BST https://twitter.com/shares_aim/status/1276114912197120000?s=20
spurslegend1
25/6/2020
09:05
Yes that's the idea. They are part of cells in the body which carry payloads within the cell. RENE have managed to functionalist them as delivery systems..
bonzo
25/6/2020
08:57
I was much struck by this report. Not directly relevant, but I imagine there are researchers in labs all over the world trying to replicate these results. Could exosomes be used as carriers? https://www.fiercebiotech.com/research/one-and-done-gene-therapy-wipes-out-parkinson-s-symptoms-mouse-models
supernumerary
25/6/2020
08:50
??? An effective delivery system to the brain is a very valuable asset...
bonzo
25/6/2020
08:31
There we are! But like Big Mac burgers, the smells not bad, but the taste...urgh
rayrac
24/6/2020
11:58
I have the sense that RENE is trying to go in this direction given the limits of its cash balance and an inability to self-finance its research through to marketable products. A similar deal like this would surely raise RENE's credibility with investors.
dickbush
23/6/2020
22:43
Big money still being paid for exosomes: https://www.fiercebiotech.com/biotech/sarepta-taps-codiak-s-exosome-tech-72-5m-neuromuscular-disease-deal Gene therapy could be a game changer for various diseases, but it can be hobbled by its packaging, most often a virus to which some people are naturally immune. Sarepta Therapeutics is on the hunt for alternatives, and its latest target is a system the body’s cells use to communicate with each other: exosomes. It is teaming up with Codiak Biosciences to develop engineered exosomes that can deliver gene therapy, gene editing or RNA-based treatments—all of which Sarepta is already working on. Under the two-year deal, Codiak will reel in up to $72.5 million in upfront and near-term license fees along with research funding, the pair said in a statement Monday. As usual, Codiak stands to pick up “significant” development and regulatory milestones, but the partners kept those numbers under wraps. [ ... ]
supernumerary
19/6/2020
11:21
Exosome program is coming to the fore and we are in an increasing number of discussions with potential collaborators https://www.youtube.com/watch?v=DxPq6_WZ-6U RENE is one for the patient, but hopefully it will be very rewarding for patients, the company and investors when things come good! Have to think positive!
lauders
17/6/2020
12:39
sn, perhaps badly expressed but, afaik, the Imperial mRNA needs to be delivered to human muscle cells for translation, so an exosome binding to the virus spike wouldn't be particularly useful. It needs to bind to the spike-receptor on the muscle cell, then merge contents so that the mRNA can be translated into a viral antigen and secreted from the muscle into body fluids. Crossing BBB may be useful but I'm not sure is relevant - the loss of smell could be peripheral.
small crow
17/6/2020
12:32
It would be worth it for in house use, but I think it would need some validation before people would pay for it.
bonzo
17/6/2020
12:27
sc - or perhaps it's just badly expressed, and they mean the exosome can deliver something that binds to spike, while carrying a killer payload such as the Imperial vaccine? That's what I would have expected, and which could provide a very useful vaccine carrier - crossing the blood-brain barrier for instance would obviously be of benefit.
supernumerary
17/6/2020
12:20
Bonzo - thought of that, but for in vitro and animal studies it surely wouldn't be worth the bother? In humans, you would presumably have already proven your vaccine was safe by trialling it in Ph1 in uninfected patients, and by the time you were up for a real Ph2 or 3, I doubt whether simply proving that you can bind to spike would be of great value.
supernumerary
Chat Pages: Latest  320  319  318  317  316  315  314  313  312  311  310  309  Older
ADVFN Advertorial
Your Recent History
LSE
RENE
Reneuron
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210508 00:38:56